...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation
【24h】

Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

机译：重组人血小表生素促进血小板植入，并改善同种异体造血干细胞移植后骨髓增生综合征患者的预后和血栓性贫血

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Poor platelet graft function (PPGF) is a significant complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no optimal treatment has been recommended. This study investigated aspects of platelet recovery after allo-HSCT, including prognostic value and the effect of recombinant human thrombopoietin (rhTPO). We retrospectively analyzed 275 patients who received allo-HSCT in our center. Of them, 135 (49.1%) patients had good platelet graft function (GPGF) and 140 (50.9%) had PPGF. The latter included 59 (21.5%) patients with primary PPGF and 81 (29.4%) with secondary PPGF. Multivariate analysis showed that male gender (P =.024), lower CD34(+) cell count (P =.04), and no use of rhTPO (P <.001) were associated with PPGF. The 3-year overall survival rate of patients with PPGF (58%) was significantly less than that of patients with GPGF (82%; P <.001). We further analyzed the effect of rhTPO on prognosis of patients after alloHSCT. Although no advantage was apparent when analyzing the entire cohort, for patients with myelodysplastic syndromes and aplastic anemia, rhTPO was associated with a significant survival advantage (P =.014). (C) 2017 American Society for Blood and Marrow Transplantation.
机译：差的血小板接枝功能（PPGF）是同种异体造血干细胞移植（Allo-HSCT）后的显着并发症。但是，没有建议使用最佳待遇。本研究研究了血小板后血小板恢复的方面，包括预后价值和重组人血小板（RHTPO）的作用。我们回顾性地分析了在我们的中心接受了Allo-HSCT的275名患者。其中，135名（49.1％）患者具有良好的血小板接枝功能（GPGF），140（50.9％）具有PPGF。后者包括59名（21.5％）初级PPGF和81（29.4％）的患者，二级PPGF。多变量分析表明，雄性性别（P = .024），降低CD34（+）细胞计数（P = .04），并且没有使用RHTPO（P <.001）与PPGF相关。 PPGF患者的3年整体存活率（58％）显着低于GPGF患者（82％; P <.001）。我们进一步分析了rhTPO对allohsct后患者预后的影响。尽管在分析整个队列时没有任何优势，但对于骨髓增生症综合征和补水性贫血患者，rHTPO与显着的存活优势有关（p = .014）。 （c）2017年美国血液和骨髓移植协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号